Becton dickinson & co（BDX.US AI Earnings Summary）
BDX AI Earnings Summary (In-Depth)
2026 Q4 (Fiscal Year)
Core Highlights
- Stock Price Reaction: Earnings were released pre-market on November 5, 2026. Despite Q4 results strongly beating market expectations, the stock price fell by as much as 5.31% to $197.50 during pre-market trading on November 5 (closing price was $209.19 on November 4). This indicates some profit-taking by the market following the strong results, as well as digestion of the slowing FY2027 guidance.
- Against Market Expectations: Revenue of approximately $5.3 billion exceeded the market consensus of $5.11 billion; adjusted EPS of $4.15 also beat the market consensus of $4.07 by approximately 2.0%.
- Against Own Guidance: All targets met or exceeded. Full-year adjusted EPS came in at $12.70, landing at the upper-middle end of the company's own guidance range ($12.62–$12.72); Q4 adjusted operating margin reached 28.6%, significantly higher than the guidance of 25%.
- In One Sentence: BECTON DICKINSON & CO completed its transformation into a pure-play medical technology company after spinning off its life sciences business, delivering stellar Q4 earnings that met all guidance; however, pre-market shares fell 5.31% to $197.50 as the market took profits and processed slowing growth for the next fiscal year.
Quarterly Highlights
Q4 FY2026 adjusted EPS and revenue both exceeded market consensus, primarily driven by simultaneous acceleration across multiple growth platforms.
Adjusted EPS significantly beat market consensus, with full-year results at the upper-middle end of company expectations: Q4 FY2026 adjusted EPS was $4.15, up 27.3% year-over-year, exceeding the market consensus of $4.07 by 2.0%. Full-year adjusted EPS was $12.70, at the upper-middle end of the $12.62 to $12.72 range provided last quarter, representing 6.7% year-over-year growth. CFO Vitor Roque stated this reflects strong revenue performance and disciplined execution.
Q4 total revenue of approximately $5.3 billion beat market consensus of $5.11 billion: On a currency-neutral basis, revenue grew 5.6% year-over-year, with all four segments showing growth. Excluding the impact of the prior year's high base comparison for Alaris, actual Q4 growth reached high-single digits, with full-year growth at solid mid-single digits, indicating sustained momentum in core business.
Advanced Patient Monitoring (APM) achieved its highest year-over-year growth in nearly 20 years: The APM segment grew 17.3% in Q4, with strong performance in both capital equipment and consumables. The HemoSphere Alta system accelerated capital equipment growth. CEO Tom Polen noted that APM performance far exceeded original acquisition model expectations and saw significant margin expansion under BD through BD Excellence manufacturing optimization.
Alaris infusion pump full-year market share increased by over 250 basis points, with a 95% attachment rate for the Incada AI platform: Alaris continued to gain market share in Q4, with cumulative full-year gains exceeding 250 basis points. The newly launched Incada AI medication management platform saw a 95% attachment rate on new Pyxis Pro installation orders. CEO Tom Polen stated this opens new avenues for recurring revenue via a Software-as-a-Service (SaaS) model.
BioPharma Systems segment grew 7.0% in Q4, with double-digit biologics growth offsetting vaccine headwinds: The biologics business continued double-digit growth driven by strong demand for GLP-1 therapies; the vaccine business declined approximately 11% in Q4, but the decline has significantly narrowed compared to mid-year. BD has signed nearly 100 agreements in the biologics space, covering new molecules and biosimilar GLP-1 programs, and completed its first commercial collaboration for the Vystra biosimilar autoinjector pen in Brazil.
Full-year Free Cash Flow increased 42% to approximately $2.9 billion, with FCF conversion rate jumping from 57% to 74%: Full-year free cash flow reached $2.933 billion, primarily benefiting from improved working capital and reduced Alaris remediation spending. BD returned $3.6 billion to shareholders during the year, including approximately $2.4 billion in share repurchases and $1.2 billion in dividends, and announced its 55th consecutive year of dividend increases.
Q4 adjusted operating margin reached 28.6%, up 280 basis points year-over-year, far exceeding the full-year target of approximately 25%: Gross margin also increased 180 basis points year-over-year to 56.8%, driven by BD Excellence productivity gains and improved product mix (higher proportion of high-margin growth platforms). Savings targets for 200 cost-reduction projects were 100% identified, and over 2,000 Kaizen improvement activities drove factory productivity up by approximately 8%.
Signed major partnership agreement with the U.S. government, gaining a potential Section 232 tariff exemption option: BD committed to investing $19 billion in the U.S. over the coming years, including $3 billion for manufacturing expansion, which represents a reallocation of existing capital rather than incremental spending. The agreement also provides future Section 232 tariff exemption protection, though this upside is not yet included in FY2027 expectations. CEO Tom Polen positioned it as a "positive option built into existing expectations."